Allogeneic stem cell transplantation (ASCT) has proved to have an important immune-mediated anti-tumour effect in patients with haematologic malignancies. There is also evidence of such an effect in patients with malignant tumours. We studied this effect of ASCT in a patient with colorectal cancer. A 77-year-old man having a primarily resected colonic cancer with disseminated lymph node involvement received ASCT from his HLA-identical sibling as the only treatment. Keywords: allogeneic stem cell transplantation; graftversus-host disease; colonic carcinoma; graft-versustumour; mixed chimerism Cancer may be controlled by the immune system as shown in experimental animal studies and in man.
myeloma and breast cancer. 12, 13 Promising results after ASCT have also been reported in patients with hypernephroma. 14, 15 Recently, more attention has been paid to the use of granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood stem cell transplantation. Comparison of G-CSF-mobilized ASCT (containing at least a 10-fold increase in donor T cell numbers) and traditional bone marrow transplantation reveals a similar incidence of GVHD and graft-versus-leukaemia (GVL) effect. [16] [17] [18] [19] Since donor T cells are the effectors of the GVL effect, it is important to study whether G-CSF-mobilized allogeneic stem cells maintain a reasonably high antitumour effect, as also in other malignancies, with a minimum of GVHD.
We wished to study the clinical contributions of the GVT effect and GVHD in a patient with colonic cancer after nonmyeloablative ASCT.
Materials and methods

Patient and donor
A 77-year-old man, who had undergone peripheral vascular surgery and coronary by-pass surgery, was diagnosed as having sigmoid cancer and underwent a left-sided hemicolectomy in April 1998. Histopathological examination revealed an adenocarcinoma Dukes C, with metastases in six of 12 local lymph nodes. With his history of severe vascular disease, he was not considered a candidate for adjuvant cytostatic therapy. At 1-year follow-up, he was found to have enlarged coeliac lymph nodes and a needle biopsy confirmed metastatic adenocarcinoma. As he had several healthy siblings, he was given the option of undergoing ASCT and was ultimately found to have a wellsuited donor in his healthy 66-year-old HLA-identical brother. ASCT for metastatic colonic carcinoma using nonmyeloablative conditioning was approved by the ethics committee at Huddinge University Hospital.
Allogeneic stem cell transplantation
The patient received fludarabine (30 mg/m 2 ) i.v. on days −4, −3 and −2 before transplantation. On the day of trans-plantation, he was treated with 2 Gy of total body irradiation (6 cGy/min). Immunosuppression with cyclosporin (CsA) was given i.v. from day −2, 1 mg/kg twice daily and orally, from day 1, 6 mg/kg twice daily. In addition, he received mycophenolate mofetil (MMF), 15 mg/kg twice daily from the day of transplantation. 20 Ciprofloxacin was given for gut decontamination. For prophylaxis against Pneumocystis carinii, he was treated with trimethoprim-sulfametoxazole, according to our protocol. 21 No antifungal prophylaxis was given. 22 
Molecular methods for monitoring mixed chimerism
DNA from donor and recipient pretransplant samples was obtained using standard protocols (Qiagen, Hilden, Germany). Separation of CD3 + , CD19 + and CD45 + cells from 4 ml of EDTA blood or gradient-separated lymph node cells at autopsy was performed with immunomagnetic beads (Dynal, Oslo, Norway). To each cell pellet, 30 l 10 mm Tris buffer was added, before freezing. After thaw- ing, 60 l lysis buffer was added to each bead-selected cell sample. These samples were then digested at 37°C overnight on a shaker, and subsequently diluted, as previously described. 23 Diluted cell lysate samples were rapidly heated to 70°C, spun and cooled on ice. Polymerase chain reaction (PCR) amplifications of two different VNTRS were used for mixed chimerism analysis. PCR parameters and the automated polyacrylamide gel system used to analyse PCR products, have also been described elsewhere. 23 
Histopathological procedures
The primary tumour in the sigmoid colon consisting of a moderately differentiated adenocarcinoma was 5 cm in diameter (Figure 1a) . Staining for ␤ 2 -microglobulin, associated with cell surface HLA class I antigens, on formalin-fixed primary tumour tissue was done using a rabbitanti-human ␤ 2 -microblobulin antibody (Dako, Glostrup, Danmark) ( Figure 1b ). The seven retrieved lymph nodes of the tumour specimen were all small, the diameter of the largest being 0.6 cm. Metastases were found in six/seven of the nodes. The tumour was consequently classified as pT3N2MX or as a Dukes C. Immunohistochemical evaluation showed that the tumour cells stained positive for CAM 5.2 (a cocktail of antibodies to high and low molecular weight cytokeratins, Dako), cytokeratin 20, carcino- embryonic antigen (CEA) and epithelial membrane antigen (EMA), but negative for cytokeratin 9 and 19.
Computed tomography (CT) examinations
CT scans of the abdomen were performed 2 months before and 2 months after stem cell transplantation ( Figure 2 ).
Results
Clinical course after transplantation
The patient received 9.8 × 10 8 MNC/kg recipient. Chimerism analysis showed 50% donor cells on CD3 and CD45 18 days after ASCT and 100% donor cells on CD3 after 28 days. One week thereafter, he developed slight GVHD of the skin which responded to steroids. CT examination 49 days after ASCT showed an 80% reduction in the size of the para-aortic lymph nodes (Figure 2a and b) . At the same time, the two lymph nodes in the supraclavicular fossa had decreased markedly in size on palpation and were not palpable 2 months after ASCT. After 3 months, when the immunosuppression was tapered, he developed moderate GVHD of the gut. Cyclosporine was reinstituted and the prednisolone dosage was increased from 20 mg once daily to 20 mg twice daily. Three weeks after this, he contracted pneumonia was treated with meropenem i.v. and itraconazole p.o. Despite an initial response with a reduction in phase reactive protein, he died 4 months after ASCT of Candida albicans pneumonia, combined with heart failure. Serum CEA values ranged from 11 g/l before transplantation to 9.4 g/l 2 months and to 7.9 g/l 3 months after transplantation. Serum CA 19.9 ranged from 9.2 kE/l before transplantation to 4.2 kE/l 2 months and to 1.6 kE/l 3 months afterwards. Serum CA50 values were 11 kE/l before transplantation, 1.4 kE/l at 2 months and were not tested at 3 months.
Histopathological post-transplant course
Fine needle aspiration from enlarged supraclavicular lymph nodes in the left supraclavicular fossa before transplantation showed an epithelial tumour, consistent with metastasis from an adenocarcinoma.
The patient was examined postmortem within 24 h of death. The heart was enlarged, weighed 495 g and the aortic valve showed slight stenosis. The left ventricle was hypertrophic and both atria were dilated. The coronary arteries had extensive atherosclerosis, but the coronary grafts showed no signs of stenosis or thrombsis. Histological examination revealed multifocal fibrosis in the myocardium, but no signs of acute infarction. Both lungs had diffuse bleeding in the lower lobes and histology showed hemorrhagic pneumonia due to Candida albicans infection. There was no tumour in the intestines. In the liver, a tumour measuring 1.2 cm in diameter was found which, on histological examination, consisted of a largely necrotic metastasis from the adenocarcinoma (Figure 3 ). Small tumour thrombi were also seen in the central and portal veins. Several enlarged lymph nodes were present; a conglomerate Bone Marrow Transplantation along the left major bronchus to the left hilar region (2.5 × 1.5 cm), three lymph nodes along the left carotid artery and in the left supraclavicular fossa (2.5, 2.5 and 1.5 cm in diameter, respectively), and a conglomerate of enlarged paraaortic lymph nodes (7.5 × 2 cm). Histological examination of the lymph nodes showed that they were all necrotic, but viable tumour cells were seen in their periphery ( Figure 4) . The immunohistochemical evaluation showed that the viable tumour tissue had the same staining pattern as the primary tumour tissue described above.
Chimerism analysis was done on cells separated from supraclavicular, paraortic and lung hilar lymph nodes postmortem. In supraclavicular and paraortic lymph nodes, 1-5% of the T cells were of donor origin, while the lung hilar lymph nodes consisted of 50% donor T cells (Table 1) . In lymph nodes, recipient T, B, myeloid and NK cells persisted despite 100% donor cell engraftment in blood.
Discussion
Here, we report a GVT effect in a patient with advanced colonic cancer, a graft-versus-colonic cancer effect. Such a specific immunologic anti-colonic cancer effect might be mediated by one or more CD8 + , CD4 + , natural killer (NK) cells, or by antibodies. Specific immunologic recognition and destruction of tumour cells require tumour-specific antigens (such as mutated ras and p53) or over-expression of rare embryonal antigens (such as CEA, MUC-1 and Her-2/neu). 24 Although such immunogenic differences between normal and cancer tissue occur, they are not large enough to have a significant anti-tumour effect in metastatic cancer. However, in allogeneic stem cell transplantation, donor lymphocytes recognising a variety of recipient antigens (including tumour antigens) with recipient antigenpresenting molecules (HLA class I and class II antigens) are transferred to the patient. A greater immunological difference between donated target lymphocytes and recipientderived tumour tissue may be one reason why ASCT is associated with an unequivocal anti-cancer effect, although the clinical benefit of this effect may be reduced by morbidity-related GVHD. [4] [5] [6] 25 In previous studies, evidence of a GVT effect has primarily been based on radiologic evidence of tumour regression, 13, 26 cell-mediated lympholysis assay 10, 13 and clinical signs of GVHD. 12, 13, 26 In more recent studies, molecular techniques to assess engraftment have been added. 14 In the present study, a relatively short post-transplantation evaluation unfortunately inhibited functional cell studies. However, we believe that the addition of histopathological postmortem evidence of specific tumour necrosis ( Figures 3  and 4) , with immunohistochemical studies of the presence of T cell target molecules (HLA class I antigens) on the patient's adenocarcinoma cells (Figure 1b) gives significant evidence of a graft-versus-colonic cancer effect even without in vitro cell studies. Further evidence includes clinical findings showing disappearance of metastases from the neck and a significant (80%) reduction in size of the abdominal lymph node metastases on CT scans (Figure 2 ). Despite rapid engraftment of CD3 + cells in blood, becoming 100% of donor type within a month after ASCT, a large number of recipient lymphoid cells persisted for 4 months in the lymph nodes ( Table 1 ). The recipient lymphoid system is a target for donor cytotoxic T cells, especially during GVHD. Therefore, it was expected that a higher proportion of donor DNA would be detected after cell separation of the lymph nodes. It cannot be excluded that part of the recipient DNA in the separated cells may be due to contaminating DNA of recipient connective tissue. However, it reveals that at 4 months, major infiltration and exchange of donor lymphoid cells has not yet taken place. Widespread necrosis was seen in the metastases, suggesting that in this case, the tumour was a major target for the donor cytotoxic T cells in contrast to the recipient lymphoid cells.
Although our patient survived only 4 months after transplantation, we were able to examine all lymph nodes with metastases. To date, we have transplanted five patients with disseminated colorectal cancer, and there are undoubtedly problems in conclusively assessing tumour regression in many patients. These patients will be reported separately with a longer follow-up and when more patients are included. It is still not known which patients with colorectal carcinoma are most suited to undergoing ASCT. From ASCT for a hematologic malignancies, we know that the tumour burden before transplantation is of utmost importance for the post-transplantation outcome. 7, 27, 28 Indeed, a pretransplantation tumour burden of only 10 10 leukaemic cells is associated with a poor prognosis after ASCT. 29 Since such a tumour burden would be equal to a solid tumour measuring 2 cm in diameter, it is tempting to speculate that such an overall tumour size may represent the upper limit of solid tumour burden that can be cured by ASCT alone. Furthermore, as the expression of HLA molecules (targets for T cell cytotoxicity) varies in different colorectal tumour cell lines, 30 it is interesting to note that our patient's adenocarcinoma stained strongly positive for HLA-class I-associated ␤ 2 -microglobulin molecules (Figure 1b) .
When a new treatment is used for the first time and for a new indication, as when ASCT is used in a patient with colorectal cancer, several ethical problems arise. As regards the prognosis, the patients selected have a poor prognosis and there is no effective treatment available for them. Therefore, in the initial phase of such trials, the advanced stage of the disease makes such patients comparable to patients transplanted for acute leukaemia in relapse or chronic myeloid leukaemia in blast crisis. Therefore, very few of the patients in initial trials are curable. At best, one may expect to see a tumour response. Initially, donors must be limited to HLA-identical siblings, because they want to give stem cells, even for an unproven indication, if they have a sibling with disseminated incurable cancer. If it has been shown that a tumour may respond and this has been confirmed in independent studies, patients at an earlier stage of the disease can also be considered for treatment with ASCT. Where there is a proven anti-tumour effect, one is more willing to take the risk of transplant-related complications, GVHD, toxicity and infections.
In summary, when patients can be treated at an earlier stage of their disease and therefore with a lower residual tumour burden, the prognosis may improve in a similar way, to that reported in acute leukaemia in remission or CML in chronic phase. 7, 27, 28 To date, we know that some malignant tumours respond to ASCT. [13] [14] [15] We would now like to add adenocarcinoma of the colon as yet another candidate for further study of the anti-cancer effect of ASCT. In the meantime, we have to find out at what stage of the disease one can intervene with ASCT. Since otherwise healthy cancer patients with a low tumour burden will probably rarely be considered for ASCT as the only palliative or adjuvant treatment, future studies will require international collaboration and, indeed, such studies are under way in the European Group for Blood and Marrow Transplantation and in the International Bone Marrow Transplantation Registry.
